Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)-Reference-Cited by-同舟云学术

Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)

Published:2022-12-29 Issue: Volume: Page:
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Cheon Jae Hee¹^ORCID,Kim Hyun-Soo²^ORCID,Han Dong Soo³^ORCID,Kim Sung Kook⁴^ORCID,Shin Sung Jae⁵^ORCID,Kim Joo Sung⁶^ORCID,Ye Byong Duk⁷^ORCID,Song Geun Am⁸^ORCID,Lee YoungJa⁹^ORCID,Kim Youngdoe⁹^ORCID,Lee Yoosun⁹^ORCID,Kim Won Ho¹^ORCID,

Affiliation:

1. Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea

2. Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea

3. Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea

4. Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea

5. Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea

6. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

7. Department of Gastroenterology, University of Ulsan College of Medicine, Seoul, Korea

8. Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea

9. Medical Affairs, Janssen Korea, Seoul, Korea

Funder

Janssen Korea Ltd

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infliximab alleviates memory impairment in rats with chronic pain by suppressing neuroinflammation and restoring hippocampal neurogenesis;Neuropharmacology;2024-03